Plus news about Longwood’s next fund and Ryzumvi’s label expansion.
EyePoint drug fails, biotech halves staff: The Watertown, MA-based biotech is letting go of
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.